Editorial board member Enrico Heffler (Humanitas University, Milan, Italy) considers the increasing evidence that both oral and inhaled corticosteroids can lead, particularly in severe asthmatics, to adverse events that have a significant impact on both patients quality of life and health-related costs.
1. What proportion of patients with asthma are classified as having severe disease? (0:12)
2. What adverse effects are associated with the use of oral and inhaled corticosteroids in patients with severe asthma? (2:19)
1. What are the impact of these adverse effects in terms of patient quality of life and overall expense? (0:12)
2. What effective strategies may be used to minimise the use of corticosteroids in these patients? (2:01)
3. What new treatment strategies are emerging for patients with severe asthma? (3:14)
Speaker disclosure: Enrico Heffler has nothing to disclose in relation to this video interview.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018.
Share this Video
Related Videos In Asthma
Andrew Menzies-Gow, ERS 2021: Personalised Treatment for Severe Asthma
It was a pleasure to meet with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to talk around personalised treatment and emerging hot topics in severe asthma. Questions How can we further personalise treatment for people with severe asthma? (0:11) What are the hot topics and latest research you are looking […]
Andrew Menzies-Gow, ERS 2021: Benralizumab Following Oral Corticosteroid Reduction in Severe Asthma
TouchRESPIRATORY got the opportunity to catch up with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to discuss oral corticosteroid (OCS) dependency in severe asthma and the use of benralizumab following OCS reduction. The abstract ‘Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study.’ (ID:1460) was presented at […]
Sarah Diver, ATS 2021: The CASCADE Study
TouchRESPIRATORY got the opportunity to catch up with Dr Sarah Diver (University of Leicester, Leicester, UK) around the CASCADE study, investigating the use of tezepelumab in patients with moderate-to-severe uncontrolled asthma. ‘Effect of tezepelumab on airway inflammatory cells, remodeling and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma: a randomized, double-blind, placebo-controlled trial’ was presented at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!